By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic-test maker Interleukin Genetics said after the close of the market Friday that it has received a delisting notice from the New York Stock Exchange's American Stock Exchange.

The firm said that the exchange has initiated delist proceedings because it has not regained compliance with certain regulations — it has stockholders' equity of less than $6 million and losses from continuing operations and/or net losses in its five most recent fiscal years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.